Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
OABI
OABI | US
1.79
USD-0.06
-3.24%
OABI | US
Loading StockChartView...
About OABI
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
13/03/2026
Close
1.79
Open
1.91
High
1.91
Low
1.77
OmniAb Inc. a biotechnology company engages in the provision of therapeutic antibody discovery technologies in the United States. The company's discovery platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals including OmniRat OmniChicken and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach and OmniTau which features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville California.
View LessOABI | US
Risk
56.3
Sharpe
-0.76
Luna's Score
48/100
Recommendation
Hold
Luna says (OABI | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
Price Below SMA10D
High Short-term Volatility
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
78.8%1 month
56.3%3 months
48.4%6 months
56.4%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
1.64
Debt to equity
0.08
Debt to assets
0.07
Ent. to EBITDA
-10.62
Ent. to rev.
20.69
PEG
-
Other Fundamentals
EBITDA
-62.02M
MarketCap
211.51M
MarketCap(USD)
211.51M
Div. yield
-
Op. margin
-247.29
Erngs. growth
-
Rev. growth
9.60
Ret. on equity
-19.87
Short ratio
19.70
Short perc.
7.70
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
0.39
Range1M
0.42
Range3M
0.58
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.63
Price X volume
336.14K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -10.62 | 0.53 | Cheaper |
| Ent. to Revenue | 20.69 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.64 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 48.41 | 72.80 | Lower Risk |
| Debt to Equity | 0.08 | -1.23 | Expensive |
| Debt to Assets | 0.07 | 0.25 | Cheaper |
| Market Cap | 211.51M | 3.66B | Emerging |
